Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Sep;78(6):828–832. doi: 10.1038/bjc.1998.587

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

R de Wit 1, G Stoter 1, D T Sleijfer 1, J P Neijt 1, W W ten Bokkel Huinink 1, L de Prijck 1, L Collette 1, R Sylvester 1
PMCID: PMC2062963  PMID: 9743309

Abstract

We investigated the efficacy and toxicity of induction chemotherapy with cisplatin and etoposide with either bleomycin or ifosfamide in patients with intermediate-prognosis testicular non-seminoma. A total of 84 eligible patients were randomized to receive four cycles of etoposide, ifosfamide, cisplatin (VIP), or four cycles of bleomycin, etoposide, cisplatin (BEP). Intermediate prognosis was defined as any of the following: lymph node metastases 5-10 cm in diameter, lung metastases more than four in number or > 3 cm, HCG 5000-50,000 IU l(-1), AFP > 1000 IU l(-1). The complete response (CR) rates to VIP and BEP were similar, 74% and 79% respectively (P = 0.62). Including the cases in whom viable cancer was completely resected with post-chemotherapy debulking surgery, the percentages of patients who achieved a no-evidence-of-disease status were 80% on VIP and 82% on BEP (P = 0.99). In addition, there were no differences in relapse rate, disease-free and overall survival after a median follow-up of 7.7 years. The 5-year progression-free survival was 85% (95% CI 74-96%) in the VIP arm and 83% (95% CI 71-96%) in the BEP arm, hazard ratio (VIP/BEP) 0.83 (95% CI 0.30-2.28). The VIP regimen was more toxic with regard to bone marrow function; the frequency of leucocytes below 2000 microl(-1) throughout four cycles was 89% on VIP and 37% on BEP (P < 0.001). Our study does not indicate that ifosfamide is superior to bleomycin in combination with cisplatin and etoposide. The sample size in this study is small as the study was prematurely discontinued when data became available from a competing study that showed no improved effectiveness of VIP compared with BEP. Taken together with these data, bleomycin should not be replaced by conventional-dose ifosfamide.

Full text

PDF
828

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Einhorn L. H. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1981 Sep;41(9 Pt 1):3275–3280. [PubMed] [Google Scholar]
  2. Einhorn L. H. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777–1781. doi: 10.1200/JCO.1990.8.11.1777. [DOI] [PubMed] [Google Scholar]
  3. Einhorn L. H., Williams S. D. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer. 1980 Sep 15;46(6):1339–1344. doi: 10.1002/1097-0142(19800915)46:6<1339::aid-cncr2820460607>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  4. Kaye S. B., Mead G. M., Fossa S., Cullen M., deWit R., Bodrogi I., van Groeningen C., Sylvester R., Collette L., Stenning S. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998 Feb;16(2):692–701. doi: 10.1200/JCO.1998.16.2.692. [DOI] [PubMed] [Google Scholar]
  5. McCaffrey J. A., Mazumdar M., Bajorin D. F., Bosl G. J., Vlamis V., Motzer R. J. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997 Jul;15(7):2559–2563. doi: 10.1200/JCO.1997.15.7.2559. [DOI] [PubMed] [Google Scholar]
  6. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  7. Motzer R. J., Cooper K., Geller N. L., Bajorin D. F., Dmitrovsky E., Herr H., Morse M., Fair W., Sogani P., Russo P. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer. 1990 Dec 15;66(12):2476–2481. doi: 10.1002/1097-0142(19901215)66:12<2476::aid-cncr2820661206>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  8. Nichols C. R., Catalano P. J., Crawford E. D., Vogelzang N. J., Einhorn L. H., Loehrer P. J. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998 Apr;16(4):1287–1293. doi: 10.1200/JCO.1998.16.4.1287. [DOI] [PubMed] [Google Scholar]
  9. Stoter G., Sylvester R., Sleijfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res. 1987 May 15;47(10):2714–2718. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES